Alexandria Real Estate Equities (ARE) has just posted its second quarter 2026 results, reporting lower sales and revenue than a year ago but a narrower quarterly net loss that investors will be weighing carefully.

The latest earnings release and the July announcement on the MAP-D precision medicine initiative come against a mixed performance backdrop for Alexandria Real Estate Equities. The share price is at US$49.74, with a 90 day share price return of 6.97%, but the 1 year total shareholder return has declined 26.57%. This suggests short term momentum has picked up while the longer term picture remains under pressure as investors reassess risk and growth potential.

If you are comparing Alexandria Real Estate Equities with other ideas in the market, this is a useful moment to scan for companies positioned around big structural themes and check out 37 power grid technology and infrastructure stocks

Bulls point to Alexandria Real Estate Equities’ niche life science portfolio and recent share price rebound. Bears focus on the revenue slide and ongoing losses. Which side does the current valuation actually lean toward next?

Most Popular Narrative: 2.5% Undervalued

The most followed narrative for Alexandria Real Estate Equities compares a fair value of $51 to the last close at $49.74 and frames the gap as modest but meaningful for patient investors.

The analysts have a consensus price target of $51.0 for Alexandria Real Estate Equities based on their expectations of its future earnings growth, profit margins and other risk factors.

However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $60.0, and the most bearish reporting a price target of just $42.0.

Want to see what underpins that $51 fair value for Alexandria Real Estate Equities? The story focuses on shifting revenue expectations, a step change in margins, and a future earnings multiple that differs from the sector playbook.

Result: Fair Value of $51 (UNDERVALUED)

However, Alexandria Real Estate Equities still faces risks from weaker biotech funding and slower leasing, which could pressure occupancy and challenge the view that the stock is currently undervalued.

Next Steps

Does this mix of pressure and potential around Alexandria Real Estate Equities reflect your own take, or does the data point you somewhere else entirely? Act while the information is fresh in your mind and review the 3 key rewards and 2 important warning signs

Looking for more investment ideas beyond Alexandria Real Estate Equities?

If Alexandria Real Estate Equities has sharpened your focus, do not stop here. Broaden your watchlist now so you keep options open instead of reacting later.

• Spot opportunities that combine quality with potential value by reviewing 52 high quality undervalued stocks before the rest of the market pays closer attention.
• Strengthen the core of your portfolio by checking companies in the solid balance sheet and fundamentals stocks screener (48 results) while prices and balance sheets still line up on your terms.
• Get ahead of the crowd by scanning the screener containing 21 high quality undiscovered gems and see which businesses could fit your next high conviction idea.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.